Great Novel Therapeutics Biotech & Medicals
Taipei Exchange 7427.TWO
Great Novel Therapeutics Biotech & Medicals Operating Income for the year ending December 31, 2023: USD -2.14 M
Great Novel Therapeutics Biotech & Medicals Operating Income is USD -2.14 M for the year ending December 31, 2023, a -17.83% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
-
Great Novel Therapeutics Biotech & Medicals Operating Income for the year ending December 31, 2022 was USD -1.82 M, a -38.11% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Operating Income for the year ending December 31, 2021 was USD -1.32 M, a -18.61% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Operating Income for the year ending December 31, 2020 was USD -1.11 M.
Key data
| Date | Operating Income | EBIT | EBITDA | Net Income |
|---|
Market news
Loading...
Taipei Exchange: 7427.TWO
| CEO | Dr. Chia-Nan Chen |
| IPO Date | July 8, 2021 |
| Location | |
| Headquarters | No.508, Zhongxiao East Road |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email